Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Conditions: Type 2 Diabetes Mellitus Interventions: Drug: Canagliflozin; Drug: DPP4 inhibitor; Drug: Liraglutide; Drug: Saxagliptin; Drug: 2nd generation Sulfonylurea Sponsors: AstraZeneca Completed

https://clinicaltrials.gov/study/NCT06099067

Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials